share_log
Moomoo 24/7 ·  04/24 07:59

Pasithea Therapeutics Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers

Pasithea Therapeutics宣布首批队列已完成其评估Ras、Nf1和Raf突变癌症Pas-004的1期试验的初始给药

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发